Back to Search
Start Over
First-line pembrolizumab plus lenvatinib for non–clear cell renal carcinomas (nccRCC): Extended follow-up of the phase 2 KEYNOTE-B61 study.
- Source :
- Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p2-2, 5p
- Publication Year :
- 2024
Details
- Language :
- English
- ISSN :
- 0732183X
- Volume :
- 42
- Database :
- Supplemental Index
- Journal :
- Journal of Clinical Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 175073878
- Full Text :
- https://doi.org/10.1200/JCO.2024.42.4_suppl.2